Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARLS adjuvant pembrolizumab versus placebo in resected early-stage NSCLC
NL-OMON53053Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in non-small cell lung cancer (NSCLC) and bronchial carcinoma comparing Pembrolizumab with Placebo (2 arms). Primary endpoints: Disease-free survival in the PD-L1 strong positive subgroup and Disease-free survival in the overall population. Started Apr 2017; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON53053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53053.